Immunome, Inc.
IMNM
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B
$26.76
▼ -1.47%
P/E
-10.54
Mkt Cap
$2.6B
52-Wk Range
$8.67–$30.06
52-Week Range
$8.67 - $30.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 184.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Novel IL-38 immune checkpoint target with limited competitive landscape
- Proprietary antibody discovery and engineering platform
- Experienced management team in immunotherapy and biopharmaceutical development
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Clinical advancement of IMM-ONC-01 in oncology indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+43.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMNM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.65 vs -$0.51 consensus (-26.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-26.5%
Revenue trend · last 8Q
—
-28%
+184%
+70%
-100%
-100%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.9M
$2.7M
$2.9M
$4.0M
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · Aug 12, 2026
vs Industry
How IMNM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related